1-4 of 4
Feng R. Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Free
Anna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, Marianne Labussiere, Karima Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boisselier, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Idbaih, Caroline Houillier, Feng R. Luo, Jean-Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petrecca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, Antonio Iavarone
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3307–3317.
https://doi.org/10.1158/1078-0432.CCR-14-2199
Published: 14 July 2015
View articletitled, Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Open the PDF for Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma in another window
Includes: Supplementary data
Journal Articles

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Free
Feng R. Luo, Zheng Yang, Amy Camuso, Richard Smykla, Kelly McGlinchey, Krista Fager, Christine Flefleh, Stephen Castaneda, Ivan Inigo, David Kan, Mei-Li Wen, Robert Kramer, Anne Blackwood-Chirchir, Francis Y. Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7180–7186.
https://doi.org/10.1158/1078-0432.CCR-06-1112
Published: 04 December 2006
View articletitled, Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Open the PDF for Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure in another window
Journal Articles

Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Free
Tai W. Wong, Francis Y. Lee, Chiang Yu, Feng R. Luo, Simone Oppenheimer, Hongjian Zhang, Richard A. Smykla, Harold Mastalerz, Brian E. Fink, John T. Hunt, Ashvinikumar V. Gavai, Gregory D. Vite
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (20): 6186–6193.
https://doi.org/10.1158/1078-0432.CCR-06-0642
Published: 24 October 2006
View articletitled, Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
Open the PDF for Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling in another window
Journal Articles

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

Free
Feng R. Luo, Zheng Yang, Huijin Dong, Amy Camuso, Kelly McGlinchey, Krista Fager, Christine Flefleh, David Kan, Ivan Inigo, Stephen Castaneda, Tai W. Wong, Robert A. Kramer, Robert Wild, Francis Y. Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5558–5565.
https://doi.org/10.1158/1078-0432.CCR-05-0368
Published: 01 August 2005
View articletitled, Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model
Open the PDF for Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model in another window